These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 35163813)

  • 21. Treatment of fabry disease: current and emerging strategies.
    Rozenfeld P; Neumann PM
    Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. α-Galactosidase aggregation is a determinant of pharmacological chaperone efficacy on Fabry disease mutants.
    Siekierska A; De Baets G; Reumers J; Gallardo R; Rudyak S; Broersen K; Couceiro J; Van Durme J; Schymkowitz J; Rousseau F
    J Biol Chem; 2012 Aug; 287(34):28386-97. PubMed ID: 22773828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developments in the treatment of Fabry disease.
    van der Veen SJ; Hollak CEM; van Kuilenburg ABP; Langeveld M
    J Inherit Metab Dis; 2020 Sep; 43(5):908-921. PubMed ID: 32083331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder.
    Yam GH; Zuber C; Roth J
    FASEB J; 2005 Jan; 19(1):12-8. PubMed ID: 15629890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
    Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
    J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endothelial Dysfunction in Fabry Disease Is Related to Glycocalyx Degradation.
    Pollmann S; Scharnetzki D; Manikowski D; Lenders M; Brand E
    Front Immunol; 2021; 12():789142. PubMed ID: 34917096
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fabry Disease: The Current Treatment Landscape.
    Lenders M; Brand E
    Drugs; 2021 Apr; 81(6):635-645. PubMed ID: 33721270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Functional Characterization and Pharmacological Evaluation of a Novel GLA Missense Mutation Found in a Severely Affected Fabry Disease Family.
    Varela P; Mastroianni Kirsztajn G; Ferrer H; Aranda C; Wallbach K; Ferreira da Mata G; Moura LA; Moreira SR; Mendes C; Curiati MA; Martins AM; Bosco Pesquero J
    Nephron; 2020; 144(3):147-155. PubMed ID: 31665721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat.
    Benjamin ER; Della Valle MC; Wu X; Katz E; Pruthi F; Bond S; Bronfin B; Williams H; Yu J; Bichet DG; Germain DP; Giugliani R; Hughes D; Schiffmann R; Wilcox WR; Desnick RJ; Kirk J; Barth J; Barlow C; Valenzano KJ; Castelli J; Lockhart DJ
    Genet Med; 2017 Apr; 19(4):430-438. PubMed ID: 27657681
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of a chemical chaperone on genetic mutations in alpha-galactosidase A in Korean patients with Fabry disease.
    Park JY; Kim GH; Kim SS; Ko JM; Lee JJ; Yoo HW
    Exp Mol Med; 2009 Jan; 41(1):1-7. PubMed ID: 19287194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No accumulation of globotriaosylceramide in the heart of a patient with the E66Q mutation in the α-galactosidase A gene.
    Kobayashi M; Ohashi T; Fukuda T; Yanagisawa T; Inomata T; Nagaoka T; Kitagawa T; Eto Y; Ida H; Kusano E
    Mol Genet Metab; 2012 Dec; 107(4):711-5. PubMed ID: 23146289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
    Germain DP; Hughes DA; Nicholls K; Bichet DG; Giugliani R; Wilcox WR; Feliciani C; Shankar SP; Ezgu F; Amartino H; Bratkovic D; Feldt-Rasmussen U; Nedd K; Sharaf El Din U; Lourenco CM; Banikazemi M; Charrow J; Dasouki M; Finegold D; Giraldo P; Goker-Alpan O; Longo N; Scott CR; Torra R; Tuffaha A; Jovanovic A; Waldek S; Packman S; Ludington E; Viereck C; Kirk J; Yu J; Benjamin ER; Johnson F; Lockhart DJ; Skuban N; Castelli J; Barth J; Barlow C; Schiffmann R
    N Engl J Med; 2016 Aug; 375(6):545-55. PubMed ID: 27509102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strong increase of leukocyte apha-galactosidase A activity in two male patients with Fabry disease following oral chaperone therapy.
    Lamari F; Mauhin W; Koraichi F; Khrouf W; Bordet C; London J; Lidove O; Charron P
    Mol Genet Genomic Med; 2019 Sep; 7(9):e894. PubMed ID: 31393666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of a novel loss-of-function mutation of the GLA gene in a Chinese Han family with Fabry disease.
    Zhou C; Huang J; Cui G; Zeng H; Wang DW; Zhou Q
    BMC Med Genet; 2018 Dec; 19(1):219. PubMed ID: 30587147
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review and recommendations for oral chaperone therapy in adult patients with Fabry disease.
    Nowicki M; Bazan-Socha S; Błażejewska-Hyżorek B; Kłopotowski MM; Komar M; Kusztal MA; Liberek T; Małyszko J; Mizia-Stec K; Oko-Sarnowska Z; Pawlaczyk K; Podolec P; Sławek J;
    Orphanet J Rare Dis; 2024 Jan; 19(1):16. PubMed ID: 38238782
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study.
    Narita I; Ohashi T; Sakai N; Hamazaki T; Skuban N; Castelli JP; Lagast H; Barth JA
    Clin Exp Nephrol; 2020 Feb; 24(2):157-166. PubMed ID: 31889231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies.
    Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Barisoni L; Jennette CJ; Bragat A; Castelli J; Sitaraman S; Lockhart DJ; Boudes PF
    Orphanet J Rare Dis; 2012 Nov; 7():91. PubMed ID: 23176611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
    Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
    J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
    Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
    PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.